The primary endpoint was HbA1c change from baseline to 24 weeks, and secondary endpoints included change in HbA1c and bodyweight at 36 weeks
Connect with us today for our compiled data, deeper discussions about the GLP-1 market or regional biotech and pharmaceutical trends
Future evidence may highlight specific populations, not yet covered by guidance, who may benefit from taking them. For food and beverage, this will create challenges as well as opportunities but staying across the science is essential for exploiting them
Instead of following a fixed escalation schedule, your physician takes into account side-effect tolerance, appetite response, weight trends, and relevant lab markers
If a Wegovy pen accidentally froze in the back of an overly cold fridge, discard it immediately